Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Rodger McEver
Oklahoma Medical Research Foundation, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Novartis AG
Intellectual property rights (e.g., royalties, patents, copyrights) not from the awardee Institution
Novartis AG is developing an antibody-based therapeutic for treating sickle cell disease. This humanized antibody to P-selectin to treat vasoocclusion in sickle cell disease is based, in part, on discoveries made by Dr. McEver. Dr. McEver’s NIH-funded research continues to study how selectins bind to ligands. Through analysis of his work, the Oklahoma Medical Research Foundation (OMRF) has determined that findings in his lab could affect the progression of Novartis' antibody-based through clinical trials and, ultimately, the product’s sales, which could potentially trigger certain milestone payments to Dr. McEver from Novartis.
Protein-glycan interactions in the vascular system
RELEVANCE: This interdisciplinary project studies how interactions of proteins with complex carbohydrates regulate the functions of blood cells, blood vessels, and a distinct set of vessels called lymphatics. The research may lead to new treatments for heart attacks, strokes, cancer, and other diseases.
Filed on March 14, 2017.
Tell us what you know about Rodger McEver's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Rodger McEver filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Rodger D. McEver | Oklahoma Medical Research Foundation | Conflict of Interest | Selexys Pharmaceuticals | >$600,000 |
| Rodger McEver | Oklahoma Medical Research Foundation | Conflict of Interest | Novartis AG | >$600,000 |
| Rodger McEver | Oklahoma Medical Research Foundation | Conflict of Interest | Novartis AG | >$600,000 |
| Rodger McEver | Oklahoma Medical Research Foundation | Conflict of Interest | Tetherex Pharmaceuticals | $20,000 - $39,999 |
| Rodger McEver | Oklahoma Medical Research Foundation | Conflict of Interest | Tetherex Pharmaceuticals | $20,000 - $39,999 |
| Rodger McEver | Oklahoma Medical Research Foundation | Conflict of Interest | Tetherex Pharmaceuticals | $20,000 - $39,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.